Physician profile
Renee Palta
NPI 1497910251
$3,383.40
in general payments reported to CMS, 2019-2025
18 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.29 · 2020: $22.36 · 2021: $23.24 · 2022: $114 · 2023: $392 · 2024: $1,343 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,077.11 |
| Education | $132.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,061.03 | 2023-2025 | |
| Genzyme Corporation | $569.78 | 2023-2025 | |
| Ardelyx, INC. | $293.25 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $240.07 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $220.19 | 2023-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $213.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $165.71 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $137.60 | 2020-2024 | Gattex, Eohilia, Entyvio |
| Celltrion USA INC. | $101.58 | 2024-2025 | Vegzelma, Zymfentra |
| Boston Scientific Corporation | $82.26 | 2021-2025 | Exalt Model D, Overstitch Endoscopic Suturing System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.80 | 2022 | |
| Celgene Corporation | $62.57 | 2023 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Pfizer INC. | $30.40 | 2024 | |
| Redhill Biopharma INC. | $28.74 | 2024 | Talicia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $23.97 | 2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $20.11 | 2025 | Vowst |
| Shire North American Group INC | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Palta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.